US Stock Market Closed

Dashboard

Brickell Biotech, Inc. (BBI)

bolt HIT FAIR VALUE

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

CEO

Robert B. Brown

Employees

15

Industry

-

Sector

-

Headquarters

Boulder

Exchange

NASDAQ

Summary Stats

Market Cap

14.5M

Revenue

479K

Net Income

-39.9M

EPS

-$0.42

Price-to-Earnings

-0.29

Price-to-Book

0.9

Debt-to-Equity

0.3

News

Analyst Ratings

Price targets projected by 2 analysts

High

$6.00

Average

$5.50

Low

$5.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Missed by -$0.02

Actual

-$0.08 -33.3%

Consensus

-0.06

Report Date

Year Ago

-0.15

Year Ago Change %

Up 46%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites